Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma [0.03%]
德瓦鲁单抗联合派姆单抗对比以铂类为基础的化疗±阿维鲁单抗用于治疗局部晚期或转移性尿路上皮癌的一线治疗adjusted比较
Ryan Dillon,Robert Jones,Aude Fléchon et al.
Ryan Dillon et al.
Background and objective: First-line (1L) treatment options for locally advanced or metastatic urothelial carcinoma (la/mUC) include enfortumab vedotin plus pembrolizumab (EV+P), based on EV-302, or platinum-based chemoth...
Genomic Prostate Score for Identifying Biologically Low-risk Disease in Patients with Prostate Cancer Undergoing Active Surveillance, Surgery, or Radiotherapy [0.03%]
前列腺癌患者的积极监测、手术或放疗中基因组前列腺评分在识别生物低危疾病中的作用
Nikita Sushentsev,Richard Colling,Renuka Teague et al.
Nikita Sushentsev et al.
Validated genomic classifiers are recommended for use when this may change the management of patients with prostate cancer (PCa). However, their potential for management de-escalation is unclear. Here, we retrospectively evaluated the 17-ge...
Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials [0.03%]
新辅助治疗为基础的肌层浸润性膀胱癌试验中根治性膀胱切除标本病理完全缓解的替代终点评估
Pietro Scilipoti,Aleksander Ślusarczyk,Constance Thibault et al.
Pietro Scilipoti et al.
Overall survival (OS) remains the gold standard end point in neoadjuvant trials for muscle-invasive bladder cancer (MIBC), yet its assessment requires prolonged follow-up. Whether pathological complete response (pCR) at radical cystectomy (...
Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter Analysis [0.03%]
BCG无反应性膀胱癌发展的预测：国际多中心分析高频非肌层浸润性膀胱癌患者中BCG无反应性疾病发展的预测：国际多中心分析
Aleksander Ślusarczyk,Marco Moschini,Wojciech Krajewski et al.
Aleksander Ślusarczyk et al.
Background: Dedicated tools estimating the risk of Bacillus Calmette-Guérin (BCG) failure among patients with high-grade (HG) non-muscle-invasive bladder cancer (NMIBC) are lacking. ...
Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients [0.03%]
根治性膀胱切除术治疗非肌层浸润性膀胱癌复发和生存的预后因素：1032例多中心分析
Mehdi Kardoust Parizi,David D&#x;Andrea,Benjamin Pradere et al.
Mehdi Kardoust Parizi et al.
Background and objective: Outcomes after radical cystectomy (RC) for non-muscle-invasive bladder cancer (NMIBC) are generally favorable, but a subset experiences recurrence and cancer-specific mortality (CSM). Tools to id...
Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials [0.03%]
同时检测到的和未检测到的前列腺癌及其对活检策略和局部治疗计划的影响：PROMIS和PICTURE试验分析
Alexander Light,Max Peters,Archana Gopalakrishnan et al.
Alexander Light et al.
Background and objective: European Association of Urology guidelines now recommend performing magnetic resonance imaging (MRI)-targeted with peri-lesional biopsies rather than traditional systematic biopsies. In patients ...
Head-to-head Comparison of Multimodal Imaging for Prostate Cancer Detection and Local Staging with Whole-mount Histopathology Reference [0.03%]
前列腺癌检测和局部分期的多模态影像方法与整张切片病理学对照的直接比较研究
Qi Miao,Anthony Sisk,Ida Sonni et al.
Qi Miao et al.
Background: Accurate detection and local staging of prostate cancer (PCa) remain critical for treatment planning, yet head-to-head multimodal imaging comparisons remain limited. ...
External Validation of the International Bladder Cancer Group Intermediate-risk Non-muscle-invasive Bladder Cancer Substratification Model [0.03%]
国际膀胱癌小组中间风险非肌层浸润性膀胱癌分层模型的外部验证
Jayant Siva,Rishi Jonnalagadda,Can Aydogdu et al.
Jayant Siva et al.
Background: Intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) represents a heterogeneous disease group with variable oncologic outcomes. To address the need for consistent risk stratification, the Internat...
Andrea Pettit,Ali J Hajiran,Steven C Campbell
Andrea Pettit
Das and colleagues showed that non-clear cell renal cell carcinoma (nccRCC) is biologically distinct from ccRCC, with frequent late recurrences and abdominal relapses. They compare three widely used surveillance frameworks and highlight key...
Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer [0.03%]
OLIGOPELVIS 2-GETUG P12研究方案：一项随机3期临床试验，在生化复发前列腺癌累及盆腔和/或腹主动脉旁淋巴结寡转移的患者中，间歇性雄激素剥夺治疗联合挽救高剂量调强放疗对比单独使用间的疗效比较
Quentin Josset,Audrey Blanc-Lapierre,Grégoire Pigne et al.
Quentin Josset et al.
Background: The management of oligorecurrent pelvic lymph nodes in patients with prostate cancer is debated. Intermittent androgen-deprivation therapy (ADT; IADT) is often proposed. Elective pelvis irradiation (ENRT) may ...